Amniotic Membrane Transplantation: A Good Treatment Option for Refractory Neurotrophic Keratitis

Mahmut Kaya* and Zeynep Ozbek

Department of Ophthalmology, Dokuz Eylul University, School of Medicine, Izmir, Turkey.

Authors’ contributions
This work was carried out in collaboration between both authors. Both authors read and approved the final manuscript.

Article Information

DOI: 10.9734/BJMMR/2015/17169

Editor(s):
(1) Thomas I. Nathaniel, Center for Natural and Health Sciences, Marywood University, PA, USA.

Reviewers:
(1) Anonymous, Tanta University Hospital, Egypt.
(2) Anonymous, Midwestern University, USA.
(3) Anonymous, Semmelweis University, Hungary.

Complete Peer review History: http://www.sciencedomain.org/review-history.php?id=1232&id=12&aid=9719

Received 1st March 2015
Accepted 22nd May 2015
Published 11th June 2015

ABSTRACT

Neurotrophic keratitis is a degenerative disease of the corneal epithelium resulting from impaired corneal innervation, possibly leading to perforation. In this report, we present a case with a history of herpetic keratitis, who developed a difficult neurotrophic ulcer despite 10 days of topical lubricant therapy and oral doxycycline. Amniotic membrane transplantation can be considered an effective alternative for treating persistent and progressive neurotrophic corneal ulcers.

Keywords: Amniotic membrane transplantation; neurotrophic keratitis; combination of graft and patch.

1. INTRODUCTION

Neurotrophic keratitis (NK) is a rare degenerative corneal disease caused by impairment of trigeminal innervation leading to corneal epithelial breakdown, impairment of healing, and development of corneal ulceration, melting, and perforation [1-3]. The distinctive feature of NK is a decrease or absence of corneal sensation [2,3]. Impairment of corneal trigeminal innervation causes morphological and metabolic epithelial disruption and leads to development of recurrent or persistent epithelial ulcers [3].
The most common causes of neurotrophic keratopathy include herpetic infection (Simplex or Zoster), intracranial space-occupying lesions, and/or neurosurgical procedures that damage the trigeminal ophthalmic branch, chemical burns, physical injuries, corneal dystrophies, chronic use of topical medications, diabetes mellitus, tumours affecting the trigeminal ganglion or sensory routes, radiation, and anterior segment surgeries [1, 3-5].

Pharmacological treatment options for NK are limited. Topical lubricants such as preservative-free artificial tears, new osmoprotective formulas and recently topical dexapanthenol may help improve the corneal surface healing in mild to moderate NK [6]. Amniotic membrane transplantation (AMT) is a surgical option for ocular surface reconstruction in the management of refractory neurotrophic corneal ulcers. AMT is relatively easy to perform, and is effective in promoting corneal epithelial healing, reducing corneal surface inflammation and neovascularization. Multilayer AMT has been proposed for treating deep neurotrophic corneal ulcers [7].

We report a patient with a history of herpetic keratitis, who developed a difficult neurotrophic ulcer despite 10 days of topical lubricant therapy and oral doxycycline.

2. CASE REPORT

A 73-year-old man presented with redness, blurred vision, and foreign body sensation in his left eye. He had been treated with topical antibiotics and artificial tears for this condition over the last four months. His past history was insignificant except cataract surgery six months ago. It was an uneventful phacoemulsification surgery in both eyes, at another institution. At the time of admission, his visual acuity was counting fingers in the left eye and his best-corrected visual acuity (BCVA) in the fellow eye was 20/20. Slit-lamp biomicroscopy revealed a paracentral deep corneal ulcer, approximately 4 x 7 mm wide (clinical stage 3 according to Mackie) [8], with hazy borders and surrounding stromal edema (Fig. 1). A corneal sensitivity test using a cotton thread revealed decreased sensation in the inferior and paracentral areas of the left cornea compared to the other locations in the left cornea and to all the locations in the right cornea. Polymerase chain reaction (PCR) was performed on the corneal scraping samples of his to test for the presence of herpes simplex virus 1 (HSV1), HSV2, and varicella zoster virus genomes.

![Fig. 1. Diffuse slit-lamp view of patient showing the area of deep corneal ulcer, stromal melting and signs of ocular inflammation (Stage 3 neurotrophic keratitis)](image-url)

PCR was positive for Herpes Simplex virus type I. A diagnosis of herpetic keratitis was made on the basis of corneal hypoaesthesia, the clinical appearance of the corneal lesion and positive PCR. Treatment was started with oral acyclovir 400 mg (Aklovir®; Sandoz, Turkey) 5 times daily, 100 mg of oral doxycycline (Monodox®; Deva, Turkey) twice a day, topical fucidic acid (Fucithalmic®; Abdi Ibrahim, Turkey) as lubricant ointment (Terramycine®; Pfizer, Turkey) twice a day and preservative-free artificial tears (Tears Naturale Free®, Alcon, USA) drops 4 times a day. The ulcer was not much different despite the above therapy (Fig. 2). Therefore, amniotic membrane transplantation (AMT) was performed on the 10th day of admission.

In eye with neurotrophic ulcer, the base of the ulcer was debrided with a microspponge and fine forceps, and the poorly adherent epithelium adjacent to the edge of the ulcer was removed up to the area where the epithelium became adherent. Then, multilayer fresh amniotic membrane was performed using combination of graft and patch technique (also called the sandwich technique) on the deep corneal ulceration with epithelium side up and the mesenchymal surface in contact with the recipient eye, and fitted to fill up the ulcer and cover the defect by trimming off the excess edges (Fig. 3). AMT was secured using 10/0 monofilament nylon sutures. A bandage contact lens was applied on top of the membrane until the membrane started to dissolve. The patient received topical prednisolon acetate 1% (Pred
Forte®; Abdi Ibrahim, Turkey) and ofloxacin 0.3% (Exocin®; Abdi Ibrahim, Turkey) ophthalmic solution four times daily for one week. Topical steroid was gradually decreased and topical antibiotic was stopped after contact lenses removal. Four weeks postoperatively, a membrane completely dissolved revealing a fully restored stromal thickness with no epithelial defect. Regular follow-up visits were scheduled every two months, and after three years of follow-up there was no corneal ulcer recurrence. On slit-lamp examination a residual stromal haze was noted, and superficial vascularization was observed across the paracentral cornea over the amniotic membrane site (Fig. 4). The final best corrected visual acuity of 20/200 was achieved.

3. DISCUSSION

Corneal healing is a complex process involving complex cellular interaction and various molecules (proteases, growth factors, and epithelial and stromal cytokines) [7,9]. Corneal neurotrophic ulcers, particularly in patients with total corneal anesthesia, are among the most difficult ophthalmological conditions to treat, and may potentially result in blindness. If the process cannot be reversed on time, it may progress toward corneal perforation or total de novo vascularization [10,11].

The treatment is based on artificial tears and the withdrawal of preserved eye drops or other types of epitheliotoxic topical medicines. Osmoprotectant compatible solutes including erythritol, glycerol, trehalose, taurine, L-carnitine may be use for protecting ocular epithelial cells [12]. If one of an osmoprotective formula is successful, one would expect this to reduce inflammation and additional cell damage. Also, tetracyclines (doxycycline and minocycline) can protect the cornea against proteolytic degradation. They inhibit matrix metalloproteinases by mechanisms independent of their antimicrobial properties, primarily through restriction of the gene expression of neutrophil collagenase and epithelial gelatinase, suppression of α1-antitrypsin degradation, and scavenging of reactive oxygen species. Recently, the antiangiogenic property of doxycycline has received increasing attention, particularly in ocular angiogenesis [13].
Autologous serum or amniotic membrane transplantation may also be used in severe cases, but their cost and safety are still under debate [14]. Recently, AMT has been successfully used to treat persistent corneal epithelial defects and ulcers from different causes, and for corneal and conjunctival surface reconstruction for a variety of ocular surface disorders [15,16]. Amniotic membrane can be performed using several different techniques such as graft, patch, and combination. Graft technique, the AM is applied as a permanent basement membrane substitute. In deep defects, e.g. corneal ulceration, multiple layers of AM can be used. Epithelialization of the AM integrates AM into the host tissue. It remains detectable for months, sometimes years, and in defects of the cornea is even colonized by local keratocytes. Patch technique, a large AM is temporarily placed on the surface of the eye as a “natural” patch. Unlike the graft technique, the AM patch typically becomes detached from the surface of the cornea after one to two weeks [17,18]. Sandwich technique is a combination of the two described above and is used mainly in serious disorders of the ocular surface such as deep and extensive corneal ulceration. This method is favored due to its high success rate (65% to 80%), and low rate of recurrence (approx. 20% to 35%) [18,19]. Amniotic membrane may express many antiangiogenic factors, antiinflammatory factors, growth factors, protease inhibitors, and immune molecules to promote the corneal ulcer healing [20,21]. Furthermore, the amniotic membrane can promote migration, adhesion, differentiation of epithelial cell, and prevent epithelial apoptosis. In corneal neurotrophic ulcers, amniotic membrane (AM) can be used to cover the exposed zone and to provide components required for reconstitution of an intact basal membrane. AM-covered surfaces have been shown to induce rapid re-epithelialization (in 2 to 4 weeks) to a smooth and wettable surface and reduce inflammation, vascularization, and scarring, thus allowing successful surface reconstruction [22]. Many researches have noted enhanced healing of wounds with the application of amniotic membrane. Also, using the amniotic membrane as a graft may prevent surface exposure and dryness because of decreased tear and blinking reflex in neurotrophic keratitis [7-9,14,15].

Lee and Tseng [23] first demonstrated the efficacy of AM in treating persistent epithelial defect from various causes while Kruse 24 successfully introduced the use of multilayer AMT for deep corneal ulcer. During a mean follow up period of 18.8 (13.0) months, all but four AMT (13/17, 76.4%) ulcers healed. Epithelialisation took place in 16.6 (9.0) days in these 13 eyes (reviewed by Lee and Tseng). Similarly, Kruse et al. [24] reported who successfully treated with multilayered AMT nine of 11 eyes with neurotrophic corneal ulcers. Prabhasawat et al. [25] transplanted amniotic membrane in 28 eyes with persistent corneal epithelial defect unresponsive to medical treatment including six eyes with limbal deficiency. They reported success rate of 82.1% in all groups with a mean follow-up of 10.9 months. We noted in this case study that ocular surface inflammation was markedly reduced following AMT. In this case, we applied the combination of techniques (sandwich technique) to prolong the durability of the membrane and increase the success rate. We achieved healing of deep corneal ulser using the combination technique (graft and patch). There was no recurrence at the treatment site during the 36-month follow-up period.

In this report, the AM was sutured as a multilayer amniotic membrane to cover the ulcerated area. When used as a combination technique, AM promotes epithelialization over it, and is frequently preserved and may become quite transparent over time. We noted in this case that ocular surface inflammation was markedly reduced following AMT. This finding may be explained in line with some recent studies showing that the stromal matrix of the amniotic membrane excludes inflammatory cells, and contains various forms of protease inhibitors [26]. It is also reported to have suppressed transforming growth factor β (TGF-β) signalling, and proliferation and myofibroblast differentiation of normal human corneal and limbal fibroblasts [27]. Herein, we summarise our experience in using AMT for persistent and progressive neurotrophic corneal ulcers.

4. CONCLUSION

Amniotic membrane transplantation may be considered as an alternative method for treating persistent neurotrophic corneal ulcers and sterile ulceration that are refractory to conventional treatment and before considering treatment by conjunctival flaps or tarsorrhaphy.
CONSENT

All authors declare that 'written informed consent was obtained from the patient for publication of this case report and accompanying images.

ETHICAL APPROVAL

It is not applicable.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Bonini S, Rama P, Olzi D, Lambiase A. Neurotrophic keratitis. Eye (Lond). 2003;17:989-95.
2. Groos EB Jr. Neurotrophic keratitis. In: Krachmer JH, Mannis MJ, Holland EJ, editors. Cornea: Clinical Diagnosis and Management. St Louis, MO, USA: Mosby; 1997.
3. Sacchetti M, Lambiase A. Diagnosis and management of neurotrophic keratitis. Clinical Ophthalmology. 2014:8 571-9.
4. Donzis PB, Mondino BJ. Management of noninfectious corneal ulcers. Surv Ophthalmol. 1987;32:94-110.
5. Hyndiuk RA, Kazarian EL, Schultz RO, et al. Neurotrophic corneal ulcers in diabetes mellitus. Arch Ophthalmol. 1977;95:2193-6.
6. Lambiase A, Rama P, Aloe L, Bonini S. Management of neurotrophic keratopathy. Curr Opin Ophthalmol. 1999;10:270-6.
7. Khokhar S, Natung T, Sony P, et al. Amniotic membrane transplantation in refractory neurotrophic corneal ulcers: A randomized, controlled clinical trial. Cornea. 2005;24:654-60.
8. Mackie IA. Neuroparalytic keratitis. In: Fraunfelder F, Roy FH, Meyer SM, editors. Current Ocular Therapy. Philadelphia, PA, USA: WB Saunders; 1995.
9. Okada Y, Reinach PS, Kitano A, Shirai K, Kao WW, Saika S. Neurotrophic keratopathy; its pathophysiology and treatment. Histol Histopathol. 2010;25:771-80.
10. Cavanagh HD, Colley AM. The molecular basis of neurotrophic keratitis. Acta Ophthalmol Suppl. 1989;192:115-34.
11. Davis EA, Dohlman CH. Neurotrophic keratitis. Int Ophthalmol Clin. 2001;41:1-11.
12. Baudouin C, Aragona P, Messmer EM, et al. Role of hyperosmolarity in the pathogenesis and management of dry eye disease: proceedings of the OCEAN group meeting. Ocul Surf. 2013;11:246-58.
13. Su W, Li Z, Li F, Chen X, Wan Q, Liang D. Doxycycline-mediated inhibition of corneal angiogenesis: an MMP-independent mechanism. Invest Ophthalmol Vis Sci. 2013;54:783-8.
14. Turkoglu E, Celik E, Alagöz G. A comparison of the efficacy of autologous serum eye drops with amniotic membrane transplantation in neurotrophic keratitis. Semin Ophthalmol. 2014;29:119-26.
15. Kruse FE, Rohrschneider K, Völcker HE. Multilayer amnioticmembrane transplantation for reconstruction of deepcorneal ulcers. Ophthalmology. 1999;106:1504-11.
16. Shimazaki J, Yang HY, Tsubota K. Amniotic membrane transplantation for ocular surface reconstruction in patients with chemical and thermal burns. Ophthalmology. 1997;104:2068-76.
17. Seitz B. Amniotic membrane transplantation. An indispensable therapy option for persistent corneal epithelial defects. Ophthalmologe. 2007;104:1075-9.
18. Sippel KC, Ma JJ, Foster CS. Amniotic membrane surgery. Curr Opin Ophthalmol. 2001;12:269-81.
19. Fuchsluger T, Tuerkeli E, Westekemper H, Esser J, Steuhl KP, Meller D. Rate of epithelialisation and re-operations in corneal ulcers treated with amniotic membrane transplantation combined with botulinum toxin-induced ptosis. Graefes Arch Clin Exp Ophthalmol. 2007;245:955-64.
20. Tseng SCG, Prabhasawat P, Barton K, et al. Amniotic membrane transplantation with or without limbal allografts for corneal surface reconstruction in patients with limbal stem cell deficiency. Arch Ophthalmol. 1998;116:431-41.
21. Prabhasawat P, Barton K, Burkett G, et al. Comparison of conjunctival autografts, amniotic membrane grafts and primary closure for pterygium excision. Ophthalmology. 1997;104:974-85.
22. Chen HJ, Pires RT, Tseng SC. Amniotic membrane transplantation for severe neurotrophic corneal ulcers. Br J Ophthalmol. 2000;84:826-33.
23. Lee S-H, Tseng SCG. Amniotic membrane transplantation for persistent epithelial defects with ulceration. Am J Ophthalmol. 1997;123:303-12.

24. Kruse FE, Rohrschneider K, Völcker HE. Multilayer amniotic membrane transplantation for reconstruction of deep corneal ulcers. Ophthalmology 1999;106:1504-11.

25. Prabhasawat P, Tesavibul N, Komolsuradej W. Single and multilayer amniotic membrane transplantation for persistent corneal epithelial defect with and without stromal thinning and perforation. Br J Ophthalmol. 2001;85:1455-63.

26. Wang MX, Gray T, Parks WC, et al. Corneal haze and apoptosis is reduced by amniotic membrane matrix in excimer laser photoablation in rabbits. J Cataract Refract Surg. 2001;27:310-9.

27. Tseng SCG, Li D-Q, Ma X. Suppression of TGF-β1, β2, β3, and TGF-β receptor II expression and myofibroblast differentiation in human corneal and limbal fibroblasts by amniotic membrane matrix. J Cell Physiol. 1999;179:325-35.